ID   GLC-82
AC   CVCL_3371
SY   Glc-82; GLC82; Gejiu Lung Carcinoma-82
DR   BTO; BTO:0004113
DR   CLO; CLO_0003505
DR   Cell_Model_Passport; SIDM01939
DR   Cosmic; 753557
DR   DepMap; ACH-001071
DR   IARC_TP53; 21345
DR   ICLC; HTL98006
DR   KCB; KCB 86017YJ
DR   KCB; KCB 200435YJ
DR   PharmacoDB; GLC82_406_2019
DR   TOKU-E; 3607
DR   Wikidata; Q54835925
RX   PubMed=2838234;
RX   PubMed=3471311;
RX   PubMed=4006684;
RX   PubMed=20545000;
RX   PubMed=25433501;
RX   PubMed=26116706;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a 32 year old female patient with a lung adenocarcinoma.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00572.
CC   Population: African American.
CC   Doubling time: 48 hours (PubMed=4006684).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Genome ancestry: African=66.32%; Native American=1.23%; East Asian, North=2.62%; East Asian, South=0%; South Asian=0%; European, North=15.73%; European, South=14.1% (PubMed=30894373).
CC   Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000067). It was one of the sources for the STR profile of this entry.
CC   Discontinued: ICLC; HTL98006; true.
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): CCRID; PubMed=26116706
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D12S391: 20,25
ST   D13S317: 12,13.3
ST   D16S539: 9,10
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 27,28
ST   D2S1338: 17
ST   D3S1358: 18
ST   D5S818: 11,12
ST   D6S1043: 18,19
ST   D7S820: 8,12
ST   D8S1179: 12,13
ST   FGA: 21
ST   Penta D: 8,15
ST   Penta E: 7,17
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=2838234;
RA   Liang M.-D., Hu M.-Y., Jia W., Wang Z.-X., Mong F.-H., Zhou K.-M.;
RT   "Establishment of a human lung alveolar cancer cell strain and its
RT   characteristics.";
RL   Zhonghua Zhong Liu Za Zhi 9:336-338(1987).
//
RX   PubMed=3471311; DOI=10.1016/0165-4608(87)90066-5;
RA   Fan Y.-S., Li P.;
RT   "Cytogenetic studies of four human lung adenocarcinoma cell lines.";
RL   Cancer Genet. Cytogenet. 26:317-325(1987).
//
RX   PubMed=4006684;
RA   Liang M.-D., Jia W., Hu M.-Y., Wang Z.-X., Liu G.-Y., Zhou K.-M.;
RT   "Establishment of lung adenocarcinoma cell line in Gejiu (GLC-82) and
RT   study of its biologic properties.";
RL   Zhonghua Zhong Liu Za Zhi 7:81-82(1985).
//
RX   PubMed=20545000; DOI=10.3724/SP.J.1141.2010.02113;
RA   Peng K.-J., Wang J.-H., Su W.-T., Wang X.-C., Yang F.-T., Nie W.-H.;
RT   "Characterization of two human lung adenocarcinoma cell lines by
RT   reciprocal chromosome painting.";
RL   Dong Wu Xue Yan Jiu 31:113-121(2010).
//
RX   PubMed=25433501; DOI=10.1007/s13277-014-2888-7;
RA   Miao Z.-F., Li W.-Y., Wang Z.-N., Zhao T.-T., Xu Y.-Y., Song Y.-X.,
RA   Huang J.-Y., Xu H.-M.;
RT   "Lung cancer cells induce senescence and apoptosis of pleural
RT   mesothelial cells via transforming growth factor-beta1.";
RL   Tumor Biol. 36:2657-2665(2015).
//
RX   PubMed=26116706; DOI=10.1096/fj.14-266718;
RA   Ye F., Chen C.-G., Qin J., Liu J., Zheng C.-Y.;
RT   "Genetic profiling reveals an alarming rate of cross-contamination
RT   among human cell lines used in China.";
RL   FASEB J. 29:4268-4272(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//